Company Description
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company in the United States.
It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also offers unbuzzd, a dietary supplement for alcohol recovery and clinical-stage healthcare solutions for emergency settings.
In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd., was founded in 1998 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Zeeshan Saeed |
Contact Details
Address: 55 University Ave., Suite 1003 Toronto, ON M5J 2H7 Canada | |
| Phone | 833-571-1811 |
| Website | quantumbiopharma.com |
Stock Details
| Ticker Symbol | QNTM |
| Exchange | NASDAQ |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001771885 |
| ISIN Number | CA74764Y2050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid and Director |
| Zeeshan Saeed | Founder, Chief Executive Officer, President and Executive Co-Chairman |
| Anthony John Durkacz | Founder and Executive Co-Chairman |
| Donal Carroll CPA | Chief Financial Officer |
| Nathan Coyle CPA | Controller |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical and Scientific Affairs |
| Dr. Ashwini Joshi | Director of Pharmaceutical Development |
| Jason D. Sawyer | Head of Finance and Mergers and Acquisitions |
| Maryann Adesso | Corporate Secretary |
| Randell Mack | President of FSD BioSciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 6-K | Report of foreign issuer |
| Apr 22, 2025 | 6-K | Report of foreign issuer |
| Apr 21, 2025 | 6-K | Report of foreign issuer |
| Apr 14, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Apr 3, 2025 | 6-K | Report of foreign issuer |
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 20-F/A | Filing |
| Mar 31, 2025 | 6-K | Report of foreign issuer |
| Mar 28, 2025 | 20-F | Annual and transition report of foreign private issuers |